Media Center Investor Relations Overview Newsroom Press Releases Company Statements InBriefs Media Center Events Stock Information Stock Quote & Chart Analyst Coverage Ownership Profile Financials SEC Filings Annual Reports Governance Governance Documents Committee Composition Investor Resources Investor FAQs Settlement Information Contact Us Investor Email Alerts Investor contact760-603-2331Email Media contact760-603-4679Email Events Upcoming events More events are coming soon. Past events Dec 19, 2024 6:45 PM EST TRYNGOLZAᵀᴹ (olezarsen) FDA approval Webcast Listen to webcast Supporting Materials View Presentation 2 MB Dec 4, 2024 9:00 AM EST Piper Sandler 36th Annual Healthcare Conference Listen to webcast Dec 3, 2024 8:45 AM EST Citi’s 2024 Global Healthcare Conference Listen to webcast Nov 20, 2024 9:00 AM EST Jefferies London Healthcare Conference Listen to webcast Nov 18, 2024 10:50 AM EST Stifel 2024 Healthcare Conference Listen to webcast Nov 13, 2024 10:30 AM EST Guggenheim Inaugural Healthcare Conference Listen to webcast Nov 13, 2024 10:15 AM EST UBS Global Healthcare Conference Listen to webcast Nov 6, 2024 11:30 AM EST Third Quarter 2024 Financial Results Webcast Listen to webcast Supporting Materials Ionis 3Q24 Earnings Slides 2.4 MB Oct 24 - Oct 28, 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting Supporting Materials ACAAI_Donidalorsen Exposure-Response Analysis Hereditary Angioedema Attack Rate versus Plasma Prekallikrein Concentration Relationship 417.3 KB ACAAI_Donidalorsen for Hereditary Angioedema Results from the OASISplus Open-Label Extension Study 288.6 KB ACAAI_Drug Patterns, Clinical Outcomes and Economic Costs among Hereditary Angioedema Patients Initiating Long-Term Prophylaxis 215.5 KB ACAAI_Impact of Donidalorsen on Patient-Reported Outcomes Results from the Phase 3 OASIS-HAE Study 213.2 KB ACAAI_Phase 2 Open-Label Extension of Donidalorsen In Patients with Hereditary Angioedema A Week 197 Analysis 259.6 KB ACAAI_Treatment Of Hereditary Angioedema Safety, Efficacy, and Patient Preference after Switching to Donidalorsen (OASISplus Study) 224.1 KB Sep 5, 2024 12:20 PM EDT Morgan Stanley 22nd Annual Global Healthcare Conference Listen to webcast
Upcoming events More events are coming soon. Past events Dec 19, 2024 6:45 PM EST TRYNGOLZAᵀᴹ (olezarsen) FDA approval Webcast Listen to webcast Supporting Materials View Presentation 2 MB Dec 4, 2024 9:00 AM EST Piper Sandler 36th Annual Healthcare Conference Listen to webcast Dec 3, 2024 8:45 AM EST Citi’s 2024 Global Healthcare Conference Listen to webcast Nov 20, 2024 9:00 AM EST Jefferies London Healthcare Conference Listen to webcast Nov 18, 2024 10:50 AM EST Stifel 2024 Healthcare Conference Listen to webcast Nov 13, 2024 10:30 AM EST Guggenheim Inaugural Healthcare Conference Listen to webcast Nov 13, 2024 10:15 AM EST UBS Global Healthcare Conference Listen to webcast Nov 6, 2024 11:30 AM EST Third Quarter 2024 Financial Results Webcast Listen to webcast Supporting Materials Ionis 3Q24 Earnings Slides 2.4 MB Oct 24 - Oct 28, 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting Supporting Materials ACAAI_Donidalorsen Exposure-Response Analysis Hereditary Angioedema Attack Rate versus Plasma Prekallikrein Concentration Relationship 417.3 KB ACAAI_Donidalorsen for Hereditary Angioedema Results from the OASISplus Open-Label Extension Study 288.6 KB ACAAI_Drug Patterns, Clinical Outcomes and Economic Costs among Hereditary Angioedema Patients Initiating Long-Term Prophylaxis 215.5 KB ACAAI_Impact of Donidalorsen on Patient-Reported Outcomes Results from the Phase 3 OASIS-HAE Study 213.2 KB ACAAI_Phase 2 Open-Label Extension of Donidalorsen In Patients with Hereditary Angioedema A Week 197 Analysis 259.6 KB ACAAI_Treatment Of Hereditary Angioedema Safety, Efficacy, and Patient Preference after Switching to Donidalorsen (OASISplus Study) 224.1 KB Sep 5, 2024 12:20 PM EDT Morgan Stanley 22nd Annual Global Healthcare Conference Listen to webcast
Dec 19, 2024 6:45 PM EST TRYNGOLZAᵀᴹ (olezarsen) FDA approval Webcast Listen to webcast Supporting Materials View Presentation 2 MB
Nov 6, 2024 11:30 AM EST Third Quarter 2024 Financial Results Webcast Listen to webcast Supporting Materials Ionis 3Q24 Earnings Slides 2.4 MB
Oct 24 - Oct 28, 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting Supporting Materials ACAAI_Donidalorsen Exposure-Response Analysis Hereditary Angioedema Attack Rate versus Plasma Prekallikrein Concentration Relationship 417.3 KB ACAAI_Donidalorsen for Hereditary Angioedema Results from the OASISplus Open-Label Extension Study 288.6 KB ACAAI_Drug Patterns, Clinical Outcomes and Economic Costs among Hereditary Angioedema Patients Initiating Long-Term Prophylaxis 215.5 KB ACAAI_Impact of Donidalorsen on Patient-Reported Outcomes Results from the Phase 3 OASIS-HAE Study 213.2 KB ACAAI_Phase 2 Open-Label Extension of Donidalorsen In Patients with Hereditary Angioedema A Week 197 Analysis 259.6 KB ACAAI_Treatment Of Hereditary Angioedema Safety, Efficacy, and Patient Preference after Switching to Donidalorsen (OASISplus Study) 224.1 KB
ACAAI_Donidalorsen Exposure-Response Analysis Hereditary Angioedema Attack Rate versus Plasma Prekallikrein Concentration Relationship 417.3 KB
ACAAI_Donidalorsen for Hereditary Angioedema Results from the OASISplus Open-Label Extension Study 288.6 KB
ACAAI_Drug Patterns, Clinical Outcomes and Economic Costs among Hereditary Angioedema Patients Initiating Long-Term Prophylaxis 215.5 KB
ACAAI_Impact of Donidalorsen on Patient-Reported Outcomes Results from the Phase 3 OASIS-HAE Study 213.2 KB
ACAAI_Phase 2 Open-Label Extension of Donidalorsen In Patients with Hereditary Angioedema A Week 197 Analysis 259.6 KB
ACAAI_Treatment Of Hereditary Angioedema Safety, Efficacy, and Patient Preference after Switching to Donidalorsen (OASISplus Study) 224.1 KB
